Missing: BioProtect's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioProtect's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioProtect
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioProtect is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
BioProtect has filed 1 patent.
Implants (medicine), Soft tissue disorders, Surgery, Soft tissue, Medical specialties
Implants (medicine), Soft tissue disorders, Surgery, Soft tissue, Medical specialties
Latest BioProtect News
Sep 1, 2022
“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea Itay Barnea They all were diagnosed with prostate cancer and shared their experience dealing with the disease. If you have been diagnosed with prostate cancer, or if you are living with the side effects of prostate cancer treatment, you are not alone. Numerous men all around the world are diagnosed with this common cancer, which affects about one in nine men. Prostate cancer is the most common non-skin cancer diagnosed in men, and the second leading cause of cancer deaths in men, after lung cancer, with more than 1.4 million men diagnosed yearly globally. (Photo: BioProtect) However, is this a real disease that eventually will find any man that will live enough years? Or do we just test too many men without any real need? Screening for prostate cancer is a long-time contentious issue in debate. Should healthy men, with no symptoms or family history of prostate cancer, get a prostate-specific antigen (PSA) test and treatment right away if a tumor is found? For more than 30 years, the PSA test has been the gold standard in prostate cancer screening. This simple, widely available blood test measures how much prostate-specific antigen is in the blood. The PSA test may identify fast-growing cancers that can spread to other parts of the body and would benefit from treatment. It may also find slow-growing cancers that are unlikely to be harmful. Some people without any symptoms of prostate cancer do choose to have regular PSA tests. But PSA tests are not perfect. PSA levels can be elevated when cancer isn't present and not elevated when cancer is present. Proponents of routine PSA testing say it is the best screening tool for detecting prostate cancer early when it is most treatable. But there are those who argue that it prompts many newly diagnosed men to seek invasive treatments that can cause many side effects, including incontinence and impotence, although up to 80% have low-risk tumors that will never be life-threatening. For them, the best option is active surveillance and watchful waiting where doctors monitor patients closely for signs that their cancer is advancing before treating it. In active surveillance, regular follow-up can include blood tests, rectal exams, and prostate biopsies to monitor cancer progression. Cancer treatment such as surgery or radiation may be suggested if tests show that cancer is progressing. Related articles: The formal clinical guidelines for prostate cancer screening and treatment, from the different relevant clinical societies, are changing back and forth, adding fuel to this debate. In the early 2000s, following two major meta-analysis studies (the European ERSPC and the American PLCO), the US Preventive Services Task Force (USPSTF) published guidelines against routine PSA tests. However, due to revisions of the leading studies and new data published, the USPSTF removed this recommendation in 2018, while the parallel Canadian task force, for example, kept its objection. Similar to the world, prostate cancer is the third most prevalent cancer disease in Israel and the most prevalent cancer among men in Israel. In 2018, 2,713 Israeli men were diagnosed with prostate cancer and about 416 died of the disease. 30,278 men diagnosed with prostate cancer since 1990 live in Israel today, 10,057 of which were diagnosed in the last five years. By international comparison, in 2020, Israel was ranked 58 in morbidity and 143 in mortality. This huge difference between morbidity and mortality factors and a high survival rate of 97%, may suggest that in Israel as well, there is a tendency of over-screening. The global prostate cancer therapeutics market size is driven by the rising numbers of prostate cancer numbers. The global market was valued at $24.9 billion in 2021, and it is predicted to exceed $24.9 billion by 2030. The market growth can be attributed to the increasing cases of prostate cancer. The rapid technological advancements in the field of oncology have led to the early diagnosis of prostate cancer among patients. This factor is likely to serve as the key factor to boost notable growth opportunities in the market. There has also been a significant increase in investment by the private and public sectors both in Israel and the world. I believe that any individual man requires a personalized, patient-centered approach to screening and treatment that one-size-fits-all screening guidelines don’t consider. The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors. If indeed, the patient has a medium or high-risk cancer, the early detection may benefit him. Up to 35% of patients undergoing prostate radiation therapy will experience radiation side effects of rectal toxicity such as rectal pain & bleeding, chronic diarrhea, urinary urgency & incontinence, cystitis, proctitis, and erectile dysfunction. For some of them, the side effects will be chronic and greatly affect their quality of life. Itay Barnea is the CEO of BioProtect, which produces biodegradable balloons for safe radiation therapy, and an Almeda Ventures portfolio company. TAGS
BioProtect Web Traffic
BioProtect Frequently Asked Questions (FAQ)
When was BioProtect founded?
BioProtect was founded in 2004.
Where is BioProtect's headquarters?
BioProtect's headquarters is located at 8 Tsor St, Tzur Yigal.
What is BioProtect's latest funding round?
BioProtect's latest funding round is Series D - II.
How much did BioProtect raise?
BioProtect raised a total of $36.25M.
Who are the investors of BioProtect?
Investors of BioProtect include Peregrine Ventures, Tchenguiz Family Office, Accelmed, KB Investment, Xenia Venture Capital and 5 more.
Who are BioProtect's competitors?
Competitors of BioProtect include Gynesonics, NinePoint Medical, GENICON, Dune Medical Devices, Magnetecs and 15 more.
Compare BioProtect to Competitors
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment.Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.
MST - Medical Smart Tools was founded in 2004 with the mission to develop image guided surgery technology solutions. The Company aims to improve laparoscopic and other minimally invasive surgical procedures and medical staff effectiveness, thus increasing hospital efficiencies, reducing surgical costs, and improving patient outcomes. MST is working within NGT, a private technological incubator in Nazareth, Israel. MST presents the market with a smart disposable Robotic Arm camera holder for laparoscopy, based on advanced image technology. The system is comprised of a computer-controlled mechanism for mechanical camera motivation, intuitive interface between the surgeon and the mechanical system. The company's R&D efforts are spearheaded by a core group of engineers with expertise in image processing, dynamics of mechanisms, multi-link systems and biomechanics. The Company is backed by strong and experienced management and professional medical advisors.
Sierra Surgical Technologies is a developer of minimally invasive surgical systems.
Perfint is a medica device company. The company's first product called - PIGA, a Tool Positioner for performing facilitating Image Guided Minimally Invasive procedures in CT environment. PIGA aims to allow radiologists to perform procedures like FNA, Biopsy, RFA in Thorax and Abdomen region more accurately.
SuturTek is a healthcare company with a patented platform technology for a portfolio of products that aim to precisely replicate traditional hand suturing techniques providing faster, easier, safer suturing in both currently sutured procedures as well as additional open and minimally invasive procedures. It's first product was for fascia closure and was followed by a sternum closing device.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.